EVOKE PHARMA INC's ticker is EVOK and the CUSIP is 30049G104. A total of 20 filers reported holding EVOKE PHARMA INC in Q1 2018. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $0 | – | 185 | +1.1% | 0.00% | – |
| Q4 2021 | $0 | – | 183 | 0.0% | 0.00% | – |
| Q3 2021 | $0 | – | 183 | 0.0% | 0.00% | – |
| Q2 2021 | $0 | – | 183 | +2.2% | 0.00% | – |
| Q1 2021 | $0 | -100.0% | 179 | -99.3% | 0.00% | – |
| Q4 2020 | $65,000 | +6400.0% | 25,117 | +17840.7% | 0.00% | – |
| Q3 2020 | $1,000 | – | 140 | +3.7% | 0.00% | – |
| Q2 2020 | $0 | – | 135 | +0.7% | 0.00% | – |
| Q1 2020 | $0 | -100.0% | 134 | -97.4% | 0.00% | – |
| Q1 2018 | $11,000 | -71.8% | 5,100 | -70.2% | 0.00% | – |
| Q4 2017 | $39,000 | +44.4% | 17,114 | +112.4% | 0.00% | – |
| Q3 2017 | $27,000 | +107.7% | 8,057 | +61.1% | 0.00% | – |
| Q2 2017 | $13,000 | -18.8% | 5,000 | 0.0% | 0.00% | – |
| Q1 2017 | $16,000 | – | 5,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 242,500 | $1,962,000 | 1.69% |
| SOPHROSYNE CAPITAL LLC | 49,000 | $397,000 | 0.40% |
| LMR Partners LLP | 23,882 | $187,000 | 0.02% |
| GEODE CAPITAL MANAGEMENT, LLC | 10,276 | $80,000 | 0.00% |
| BlackRock Investment Management, LLC | 489 | $4,000 | 0.00% |
| MORGAN STANLEY | 500 | $4,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 84 | $1,000 | 0.00% |
| VANGUARD GROUP INC | 48,394 | $378,000 | 0.00% |
| UBS AG | 727 | $6,000 | 0.00% |
| BANK OF AMERICA CORP /DE/ | 33,500 | $271,000 | 0.00% |